Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A market-focused analysis of Johnson & Johnson shares highlights a divergence between discounted cash-flow estimates and the company’s earnings-driven valuation metrics.
THE APEX TIMES
THE APEX TIMES
The company said it is advancing seltorexant for major depressive disorder into late-stage development and is expanding its outpatient approach in cardiology, indicating continued emphasis on specialty care across mental health and cardiovascular disease.
THE APEX TIMES
A market-focused report says Johnson & Johnson’s stock is up more than 50% over the past year and is nearing its 52-week peak. The same analysis points to potential pressure points, including how richly the shares are priced, what insider trading suggests, and how the company’s product pipeline could shape results.
THE APEX TIMES
The FDA authorization for J&J’s OTTAVA soft-tissue robotic surgery system and ongoing movement around talc litigation and settlements may change how investors weigh near-term growth versus headline legal exposure.
THE APEX TIMES
Johnson & Johnson said fiscal second-quarter revenue rose 6.6% year over year to $25.31 billion, exceeding the roughly $25.05 billion average analysts expected, as the market compares the healthcare giants’ post-earnings positioning.
THE APEX TIMES
After reporting fiscal Q2 2026 results, Johnson & Johnson leaned on broad sales momentum that beat Wall Street’s average estimate, raising the bar for how investors will weigh its outlook against Abbott Laboratories’ performance after its own earnings period.
THE APEX TIMES
FDA De Novo authorization gives Johnson & Johnson’s robotic surgical system a clearer path to adoption in the U.S., intensifying competition with Intuitive Surgical, the dominant player in surgical robotics.
THE APEX TIMES
A new report highlights Johnson & Johnson’s continued dividend increases, extending a decades-long record even as the stock’s recent rise trims the dividend yield. The article also points to a fresh growth push as part of the company’s forward plan.
THE APEX TIMES
The company said it reached a US$5.5 billion agreement aimed at resolving tens of thousands of lawsuits tied to allegations that talc-containing baby powder caused health harms. Terms were not fully detailed in the report.
